- Home
- et cancer
- Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
4.7 (465) · $ 32.99 · In stock
PDF] Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression
Heterogeneity of triple negative breast cancer: Current advances
Cluster analysis of the triple-negative breast cancer (TNBC) subtype
Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer, Experimental Hematology & Oncology
Multi-omics analysis identifies therapeutic vulnerabilities in
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Model identification using representative genes in human
Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics - RSC Advances (RSC Publishing) DOI:10.1039/D2RA02005J
Long Non-Coding RNAs in Triple-Negative Breast Cancer
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
